Olfactory dysfunction is common among patients with Corona-Virus-Infection-Disease
(COVID)-19, and up to 30% of patients may report persistent disorders of smell or taste as a
long-term sequelae. This randomized-controlled study has addressed to compare the efficacy of
neuro-protective and anti-inflammatory agents palmitoylethanolamide (PEA) and
Luteolin(Treatment) with control (olfactory training) in a cohort of patients who present
persistent smell disorders after resolution from Covid-19 and negative swab for 4 months at
least.
Phase:
Phase 4
Details
Lead Sponsor:
University Of Perugia
Collaborators:
Azienda Ospedaliera Ospedali Riuniti Marche Nord, Italy Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo Azienda Ospedaliero Universitaria di Sassari Azienda Ospedaliero-Universitaria Careggi Federico II University Humanitas Hospital, Italy Istituto per la Sicurezza Sociale (ISS) della Repubblica di San Marino Ospedale Bufalini di Cesena, Italy Ospedale Universitario di Genova, Italy Policlinico Universitario, Catania San Giovanni Addolorata Hospital